A wrinkle-removing composition, its preparation method and use

Abstract

This invention provides an anti-wrinkle composition, its preparation method, and its application, relating to the field of cosmetic technology. The anti-wrinkle composition comprises the following raw materials: oligopeptide-29, acetyl dipeptide-1 cetyl ester, palmitoyl hexapeptide-12, echinacea extract, oat extract, and red clover extract. This invention achieves synergistic effects through the scientific combination of specific peptides and plant extracts, possessing multiple benefits including safety and gentleness, firming and wrinkle reduction, skin barrier repair, and accelerated skin metabolism. It solves the technical problems of existing anti-wrinkle products, such as single active ingredient action pathways, limited wrinkle-reducing effects, and insufficient gentleness. Its preparation method is simple, the process is stable, and the production cost is controllable, making it widely applicable in various anti-wrinkle and anti-aging cosmetics, with promising market prospects.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, specifically to an anti-wrinkle composition, its preparation method, and its application. Background Technology

[0002] Skin aging is a complex process resulting from the combined effects of endogenous physiological functional decline and exogenous environmental damage, and it remains a core research focus in the cosmetics field. With age, the activity of skin fibroblasts declines, the synthesis of type I and type III collagen and elastin decreases, and their degradation accelerates. The supporting structure of the dermis gradually loosens, leading to static wrinkles. Repeated contractions of facial muscles over a long period deepen dynamic wrinkles, eventually solidifying them into permanent lines. External factors such as UV radiation, environmental pollution, and oxidative stress further induce the overexpression of matrix metalloproteinases (MMPs), exacerbating collagen loss and barrier damage, making dryness, roughness, dullness, and wrinkles more pronounced. Therefore, developing multi-pathway synergistic anti-wrinkle products that simultaneously target wrinkle reduction, oxidative damage, and barrier repair has significant market value and technological importance.

[0003] Currently, commonly used anti-wrinkle ingredients in cosmetics are mainly divided into two categories: peptides and plant extracts. Chinese patent application CN118955618A discloses an anti-wrinkle peptide, a peptide-containing composition, and its application. Through fermentation with *Lactobacillus rhamnosus* and *Streptococcus thermophilus*, followed by Sephadex G-15 filtration and reversed-phase high-performance liquid chromatography (RP-HPLC) purification, a nonapeptide-III active peptide with significant elastase inhibitory activity and antioxidant activity was obtained. In addition to its good antioxidant and elastase inhibitory effects, the composition containing this peptide also improves the wrinkle reduction rate and reduces the proportion of wrinkle area, thus achieving a better anti-wrinkle effect. Active peptides, due to their strong targeting and clear mechanism of action, have become core ingredients in high-end anti-wrinkle products: for example, neurotransmitter inhibitory peptides can relieve excessive muscle contraction and improve expression lines; collagen-promoting peptides can activate fibroblasts and increase collagen and elastin content. However, single peptides usually act only on a single pathway, with limited improvement on skin barrier, oxidative stress, and keratin metabolism, making it difficult to achieve a comprehensive anti-wrinkle effect.

[0004] Chinese patent application CN107616949A discloses an anti-wrinkle and freckle-removing composition comprising jasmine seed endosperm extract, ginkgo leaf extract, narcissus bulb extract, and winter melon peel extract, wherein the mass ratio of the jasmine seed endosperm extract, ginkgo leaf extract, narcissus bulb extract, and winter melon peel extract is (1-10):(1-5):(1-5):(1-5). Plant extracts possess multiple advantages, including gentleness and safety, multi-target synergy, and combined antioxidant, soothing, repairing, and metabolism-promoting effects. They can assist in improving aging skin by scavenging free radicals, strengthening the skin barrier, and accelerating cell renewal. However, most commercially available products still rely on single plant extracts or single peptides, lacking a systematic approach that scientifically combines the two to achieve complementary and synergistic effects. Some compounded products suffer from poor compatibility, unstable activity, overlapping pathways of action, and insignificant wrinkle-removing effects, failing to meet consumers' demands for highly effective, gentle, and long-lasting wrinkle removal.

[0005] In summary, existing technologies lack a comprehensive anti-wrinkle composition that synergistically combines peptides and plant extracts to simultaneously inhibit dynamic wrinkles, promote collagen synthesis, provide antioxidant effects, repair the skin barrier, and accelerate skin metabolism. Therefore, this invention aims to provide an anti-wrinkle composition with significant synergistic effects, good stability, and gentle safety. Through a scientifically formulated ratio of specific peptides and plant extracts, it overcomes the limitations of single-ingredient efficacy, improving skin aging wrinkles from multiple dimensions, enhancing skin firmness, elasticity, and radiance, and addressing the shortcomings of existing technologies. Summary of the Invention

[0006] To address the aforementioned problems, this invention provides an anti-wrinkle composition that significantly improves the anti-wrinkle effect through the combination of specific peptides and specific plant extracts.

[0007] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0008] On one hand, the present invention provides an anti-wrinkle composition comprising the following ingredients: oligopeptide-29, acetyl dipeptide-1 cetyl ester, palmitoyl hexapeptide-12, echinacea extract, oat extract and red clover extract.

[0009] Preferably, the mass ratio of oligopeptide-29, acetyl dipeptide-1 cetyl ester, and palmitoyl hexapeptide-12 is 0.8-1.2:0.8-1.2:3-5.

[0010] Any point value or sub-range value within the range of 0.8-1.2:0.8-1.2:3-5 is applicable to this invention, including but not limited to 0.8:0.8:3, 0.8:0.9:3, 0.8:1:3, 0.8:1.1:3, 0.8:1.2:3, 0.8:0.8:4, 0.8:0.9:4, 0.8:1:4, 0.8:1.1:4, 0.8:1.2:4, 0.8:0.8:5, 0.8:0.9:5, 0.8:1:5, 0.8:1.1:5, 0.8: 1.2:5, 0.9:0.8:3, 0.9:0.8:3, 0.9:1:3, 0.9:1.1:3, 0.9:1.2:3, 0.9:0.8:4, 0.9:0.8:4, 0.9:1:4, 0.9:1.1:4, 0.9:1.2:4, 0.9:0.8:5, 0.9:0.8:5, 0.9:1:5, 0.9:1.1:5, 0.9:1.2:5, 1:0.8:3, 1:0.8:3, 1:1:3, 1:1.1:3, 1:1. 2:3, 1:0.8:4, 1:0.8:4, 1:1:4, 1:1.1:4, 1:1.2:4, 1:0.8:5, 1:0.8:5, 1:1:5, 1:1.1:5, 1:1.2:5, 1.1:0.8:3, 1.1:0.8:3, 1.1:1:3, 1.1:1.1:3, 1.1:1.2:3, 1.1:0.8:4, 1.1:0.8:4, 1.1:1:4, 1.1:1.1:4, 1.1:1.2:4, 1.1:0.8: 5, 1.1:0.8:5, 1.1:1:5, 1.1:1.1:5, 1.1:1.2:5, 1.2:0.8:3, 1.2:0.8:3, 1.2:1:3, 1.2:1.1:3, 1.2:1.2:3, 1.2:0.8:4, 1.2:0.8:4, 1.2:1:4, 1.2:1.1:4, 1.2:1.2:4, 1.2:0.8:5, 1.2:0.8:5, 1.2:1:5, 1.2:1.1:5, 1.2:1.2:5.

[0011] More preferably, the mass ratio of oligopeptide-29, acetyl dipeptide-1 cetyl ester, and palmitoyl hexapeptide-12 is 1:1:4.

[0012] Preferably, the mass ratio of the purple coneflower extract, oat extract and red clover extract is 3-5:5-7:0.5-1.5.

[0013] Any point value or sub-range value within the range of 3-5:5-7:0.5-1.5 is applicable to this invention, including but not limited to 3:5:0.5, 3:6:0.5, 3:7:0.5, 3:5:0.6, 3:6:0.6, 3:7:0.6, 3:5:0.7, 3:6:0.7, 3:7:0.7, 3:5:0.8, 3:6:0.8, 3:7:0.8, 3:5:0.9, 3:6:0.9, 3:7:0.9, 3:5:1.0, 3:6:1.0, 3:7:1.0, 3:5:1.1, 3:6:1.1, and 3:7:1. 1. 3:5:1.2. 3:6:1.2. 3:7:1.2. 3:5:1.3. 3:6:1.3. 3:7:1.3. 3:5:1.4. 3:6:1.4. 3:7:1.4. 3:5:1.5. 3:6:1.5. 3:7:1.5. 4:5:0.5. 4:6:0.5. 4:7:0.5. 4:5:0.6. 4:6:0.6. 4:7:0.6. 4:5:0.7. 4:6:0.7. 4:7:0.7. 4:5:0.8. 4:6:0.8. 4:7:0.8. 4:5:0.9. 4:6: 0.9, 4:7:0.9, 4:5:1, 4:6:1, 4:7:1, 4:5:1.1, 4:6:1.1, 4:7:1.1, 4:5:1.2, 4:6:1.2, 4:7:1.2, 4:5:1.3, 4:6:1.3, 4:7:1.3, 4:5:1.4, 4:6:1.4, 4:7:1.4, 4:5:1.5, 4:6:1.5, 4:7:1.5, 5:5:0.5, 5:6:0.5, 5:7:0.5, 5:5:0.6, 5:6:0.6, 5:7:0.6, 5:5:0.7, 5 :6:0.7, 5:7:0.7, 5:5:0.8, 5:6:0.8, 5:7:0.8, 5:5:0.9, 5:6:0.9, 5:7:0.9, 5:5:1.0, 5:6:1.0, 5:7:1.0, 5:5:1.1, 5:6:1.1, 5:7:1.1, 5:5:1.2, 5:6:1.2, 5:7:1.2, 5:5:1.3, 5:6:1.3, 5:7:1.3, 5:5:1.4, 5:6:1.4, 5:7:1.4, 5:5:1.5, 5:6:1.5, 5:7:1.5.

[0014] More preferably, the mass ratio of the purple coneflower extract, oat extract, and red clover extract is 4:6:1.

[0015] Preferably, the ratio of the total mass of oligopeptide-29, acetyl dipeptide-1 cetyl ester, and palmitoyl hexapeptide-12 to the total mass of echinacea extract, oat extract, and red clover extract is 5-10:50-70.

[0016] Any point value or sub-range value within the range of 5:50-70 is applicable to this invention, including but not limited to 5:50, 5:51, 5:52, 5:53, 5:54, 5:55, 5:56, 5:57, 5:58, 5:59, 5:60, 5:61, 5:62, 5:63, 5:64, 5:65, 5:66, 5:67, 5:68, 5:69, 5:70, 6:50, 6:51, 6:52, 6:53, 6:54, 6:55, 6:56, 6:57, 6:58, 6:59, 6:60, 6:61, 6:62, 6:63, 6:64, 6:65, 6:66, 6:67, 6:68, 6:69, 6:70, 7:50, 7:51, 7:52, 7:53, 7:54, 7:55, 7:56, 7:57, 7:58, 7:59, 7:60, 7:61, 7:62, 7:63, 7:64, 7:65, 7:66, 7:67, 7:68, 7: 69, 7:70, 8:50, 8:51, 8:52, 8:53, 8:54, 8:55, 8:56, 8:57, 8:58, 8:59, 8:60, 8:61, 8:62, 8:63, 8:64, 8:65, 8:66, 8:67, 8:68, 8:69, 8:70, 9:50, 9:51, 9:52, 9:53, 9:54, 9:55, 9:56, 9:57, 9:58, 9:59, 9:60, 9:61 9:62, 9:63, 9:64, 9:65, 9:66, 9:67, 9:68, 9:69, 9:70, 10:50, 10:51, 10:52, 10:53, 10:54, 10:55, 10:56, 10:57, 10:58, 10:59, 10:60, 10:61, 10:62, 10:63, 10:64, 10:65, 10:66, 10:67, 10:68, 10:69, 10:70.

[0017] More preferably, the ratio of the total mass of oligopeptide-29, acetyl dipeptide-1 cetyl ester, and palmitoyl hexapeptide-12 to the total mass of echinacea extract, oat extract, and red clover extract is 8:60.

[0018] Secondly, the present invention provides a method for preparing the above-mentioned anti-wrinkle composition, comprising the following steps: mixing raw materials.

[0019] Thirdly, the present invention provides the application of the above-mentioned anti-wrinkle composition in the preparation of cosmetics.

[0020] Preferably, the dosage form of the cosmetic includes aqueous solution, ointment, cream, emulsion, gel, aerosol, spray or injection.

[0021] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention scientifically combines three active polypeptides—oligopeptide-29, acetyl dipeptide-1 cetyl ester, and palmitoyl hexapeptide-12—with extracts of purple coneflower, oat, and red clover. The components produce a significant synergistic effect, achieving skin anti-wrinkle and repair from multiple targets and pathways, overcoming the shortcomings of single active ingredients with limited mechanisms of action and wrinkle-reducing effects.

[0022] 2. The specific polypeptide components of this invention can act on the dermis layer of the skin, promoting the synthesis of collagen and elastin, improving skin laxity, reducing dynamic and static wrinkles, and achieving firming, smoothing, and wrinkle-reducing effects. Plant extracts provide antioxidant, anti-inflammatory, soothing, and repairing effects, enhancing skin tolerance, reducing the risk of irritation, and improving the product's gentleness and safety. This specific composition is remarkably effective in firming the skin, reducing wrinkles, brightening skin tone, repairing the skin barrier, and accelerating skin metabolism. Long-term use can delay skin aging and improve various skin problems such as roughness, dryness, fine lines, and sagging, resulting in outstanding comprehensive anti-aging effects.

[0023] 3. The ingredients of this invention are mild and non-irritating, suitable for a wide range of skin types, and are unlikely to cause discomfort such as sensitivity and redness. It balances efficacy and safety, and solves the problem of insufficient gentleness in traditional strong anti-wrinkle products.

[0024] 4. The preparation method provided by this invention is simple, mild, reproducible, easy to industrialize, has stable raw material sources, and controllable costs. It is suitable for large-scale preparation and application in various anti-wrinkle and anti-aging cosmetics such as serums, lotions, creams, and masks, and has broad market application and promotion value. Detailed Implementation

[0025] To make the technical means, creative features, achieved objectives, and effects of this invention readily understandable, the invention is further illustrated below with specific embodiments. However, these embodiments are merely preferred embodiments and not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments described herein without creative effort are all within the scope of protection of this invention. It is worth noting that the raw materials used in this invention are all common commercially available products, and their sources are not specifically limited. The technical and scientific terms used in the embodiments have the meanings commonly understood by those skilled in the art to which this invention pertains.

[0026] Oligopeptide-29: Purchased from Gansu Yishengxiang Biotechnology Co., Ltd., purity 98%; Acetyl dipeptide-1 cetyl ester: purchased from Wuhan Beileye Biomedical Technology Co., Ltd., CAS No.: 196604-48-5, brand Beileye; Palmitoyl hexapeptide-12: Purchased from Jiangsu Maikai Biotechnology Co., Ltd., CAS No.: 171263-26-6, with an active ingredient content of 99%.

[0027] Purple coneflower extract: purchased from Shaanxi Future Boundary Biotechnology Co., Ltd., product number SXBJ-20251026; Oat extract: purchased from Shaanxi Kangzhou Biotechnology Co., Ltd., oat β-glucan content 90%, product number KZ2025070406-01; Red clover extract: purchased from Xi'an Aosai Biotechnology Co., Ltd., specification 10:1.

[0028] Example 1 An anti-wrinkle composition, comprising, by weight, the following raw materials: 1.3 parts oligopeptide-29, 1.3 parts acetyl dipeptide-1 cetyl ester, 5.4 parts palmitoyl hexapeptide-12, 21.8 parts echinacea extract, 32.7 parts oat extract and 5.5 parts red clover extract are mixed evenly to obtain the final product.

[0029] Example 2 An anti-wrinkle composition, comprising, by weight, the following raw materials: 1.6 parts oligopeptide-29, 2.4 parts acetyl dipeptide-1 cetyl ester, 6 parts palmitoyl hexapeptide-12, 14.3 parts echinacea extract, 33.3 parts oat extract and 2.4 parts red clover extract are mixed evenly to obtain the final product.

[0030] Example 3 An anti-wrinkle composition, comprising, by weight, the following raw materials: Mix 0.8 parts of oligopeptide-29, 0.6 parts of acetyl dipeptide-1 cetyl ester, 3.6 parts of palmitoyl hexapeptide-12, 30.4 parts of purple coneflower extract, 30.4 parts of oat extract and 9.1 parts of red clover extract evenly to obtain the final product.

[0031] Comparative Example 1 An anti-wrinkle composition, compared with Example 1, differs only in the amount of raw materials used, specifically as follows: The product is composed of the following raw materials in parts by weight: 5.3 parts oligopeptide-29, 0.3 parts acetyl dipeptide-1 cetyl ester, 2.4 parts palmitoyl hexapeptide-12, 15 parts purple coneflower extract, 15 parts oat extract and 30 parts red clover extract. The raw materials are mixed evenly to obtain the product.

[0032] Comparative Example 2 An anti-wrinkle composition, compared with Example 1, except that acetyl dipeptide-1 cetyl ester is replaced with acetyl hexapeptide-8, and the rest is the same as Example 1.

[0033] Comparative Example 3 An anti-wrinkle composition, compared with Example 1, except that oligopeptide-29 is replaced with oligopeptide-1, and the rest is the same as Example 1.

[0034] Comparative Example 4 An anti-wrinkle composition, compared with Example 1, except that the echinacea extract is replaced with chrysanthemum extract, and the rest is the same as Example 1.

[0035] Test Example 1 Safety: Patch Test Human patch test Experimental Procedure: A total of 30 subjects were randomly selected based on their gender and age composition (meeting the inclusion and exclusion criteria of the "Diagnostic Criteria and Treatment Principles for Cosmetic Contact Dermatitis"). Qualified patch materials were used. The compositions prepared in Examples 1-3 and Comparative Examples 1-4 were mixed with white petrolatum at a 1:1 mass ratio and ground into a uniform paste / ointment. This paste / ointment was added to the patch applicator as the sample group, with the control well serving as the blank control (white petrolatum). Both the sample group and the blank control were applied to the flexor side of the forearm of each subject (each subject had 8 application points, corresponding to the samples prepared in Examples 1-3 and Comparative Examples 1-4, and the blank control, respectively). The patches were gently pressed with the palm of the hand to ensure even application to the skin, and left for 24 hours. After removing the patch applicator, the skin reaction was observed after a 30-minute interval until the pressure marks disappeared. Skin reactions were observed again at 24 hours and 48 hours after the patch test.

[0036] Judgment criteria: According to the "Diagnostic Criteria and Treatment Principles for Contact Dermatitis Caused by Cosmetics", the following classifications are used: no reaction at the test site (Grade 0), light red spots on the skin (Grade 1), erythema, infiltration or papules on the skin (Grade 2), edematous erythema and papules on the skin (Grade 3), and significant redness and swelling on the skin with papules or bullae (Grade 4).

[0037] If more than two out of 30 cases experience grade 2 adverse skin reactions, or if any one case experiences a grade 3 or higher adverse skin reaction, the test substance is deemed to have an adverse effect on the human body.

[0038] The specific results are shown in Table 1 below: Table 1

[0039] The results show that the compositions prepared in Examples 1-3 and Comparative Examples 1-4 of this invention have no adverse reactions on the human body.

[0040] Test Example 2 Free radical scavenging rate Test samples: Take the compositions prepared in Examples 1-3 and Comparative Examples 1-4 and prepare a 10 mg / mL stock solution with 50% (v / v) ethanol aqueous solution. Sonicate for 15-30 min to ensure uniform dispersion. Centrifuge the prepared solution at 4000 rpm for 10 min or filter it through a 0.45 μm microporous membrane. Take the supernatant as the test sample for subsequent experiments.

[0041] (1) Hydroxyl radical scavenging rate: Method: Take 1.0 mL of 1.865 mmol / L o-phenanthroline anhydrous ethanol solution into a stoppered test tube, and add 2.0 mL of 0.2 mol / L pH 7.4 phosphate buffer.

[0042] Sample tube (A_sample): Add 1.0 mL of the sample to be tested, mix well, then add 1.0 mL of FeSO4·7H2O solution with a concentration of 1.865 mmol / L, mix well again, and then add 1.0 mL of 0.03% (v / v) H2O2 solution.

[0043] Model control tube (A_model): The test sample is replaced with a 50% ethanol aqueous solution, and the other reagents are the same as the sample tube (containing H2O2).

[0044] Normal control tube (A_normal): Replace the test sample with 50% ethanol aqueous solution, replace H2O2 solution with distilled water, and use the same reagents as the test tube.

[0045] Sample background tube (A_background): Add 1.0 mL of the sample to be tested. The other reagents are the same as in the sample tube, but distilled water is used instead of H2O2 solution (to subtract the interference of the sample's own color).

[0046] Each group of test tubes was reacted in a constant temperature water bath at 37℃ for 60 min. After the reaction, the tubes were cooled to room temperature, and the absorbance of each tube was measured at a wavelength of 536 nm.

[0047] The scavenging rate of hydroxyl radicals is calculated using the following formula: Hydroxyl radical scavenging rate (%) = {[(A_sample - A_background) - A_model] / (A_normal - A_model)} × 100%; A is the absorbance value at 536 nm read from the spectrophotometer.

[0048] The average value of the three measurements was taken, and the test results are shown in Table 2.

[0049] (2) DPPH free radical scavenging rate: Method: Take 3 mL of 0.0178 mmol / L DPPH anhydrous methanol solution into a cuvette.

[0050] Sample tube (A_sample): Add 3 mL of the sample to be tested and mix well.

[0051] Blank control tube (A_control): Add 3 mL of 50% ethanol aqueous solution (in place of the sample).

[0052] Sample background tube (A_background): Take 3 mL of anhydrous methanol (instead of DPPH solution) and add 3 mL of the sample to be tested (to subtract the color interference of the sample itself).

[0053] After mixing all groups thoroughly, store at 37°C in the dark for 30 min. Measure the absorbance at 517 nm. Calculate the DPPH radical scavenging rate using the following formula: DPPH radical scavenging rate (%) = [A_control - (A_sample - A_background)] / A_control × 100%; A is the absorbance value at 536 nm read from the spectrophotometer.

[0054] The average value of the three measurements was taken, and the test results are shown in Table 2.

[0055] Table 2

[0056] The results show that the compositions prepared in Examples 1-3 and Comparative Examples 1-4 of this invention have better free radical scavenging effects, that is, better anti-aging effects.

[0057] Test Example 3 Human trial evaluation experiment (1) Test subjects: Test groups 1-3: Anti-aging and wrinkle-reducing serums containing the compositions of Examples 1-3.

[0058] Control groups 1-4: Anti-aging and wrinkle-reducing serums containing the compositions of comparative examples 1-4.

[0059] Control group 2: Blank matrix essence (moisturizer and solvent, no active ingredients).

[0060] The raw materials and preparation methods of the serum are shown in Table 3 below: Table 3

[0061] Preparation method: a. Solvent pre-preparation: In a clean stainless steel reactor, add the solvent, start stirring (100-150 rpm), slowly add the humectant, and stir until completely dissolved to form a homogeneous humectant phase.

[0062] b. Addition of active ingredients: Add the active ingredients slowly while stirring continuously, controlling the addition rate to keep the system temperature below 40°C to avoid deactivation of heat-sensitive ingredients.

[0063] c. Homogenization and Stabilization: Heat the system to 45℃ and homogenize it three times using a high-pressure homogenizer (15-20 MPa), each time for 2 minutes, to ensure uniform dispersion of the active ingredients and improve permeability and stability. Cool to below 30℃, let stand for 24 hours to defoam, filter through a 0.22 μm terminal filter, aseptically fill into light-proof containers, seal and store in a cool place (≤25℃).

[0064] (2) Subjects and method of use: The above-described serum was used in the experiment: 80 subjects were divided into 10 groups and numbered 1-10. The subjects used the serum on their faces twice a day for one month.

[0065] Usage: Subjects used the corresponding group serum (approximately 0.5g each time) once in the morning and once in the evening after cleansing, for 28 consecutive days (4 weeks).

[0066] Environmental control: The test was conducted in a constant temperature (21±1℃) and constant humidity (50±5%) environment.

[0067] Cleansing period: Subjects must not use other functional skin care products on their face for 12 hours before and during the test.

[0068] Test time points: the day of use (D0), 14 days after use (D14), and 28 days after use (D28).

[0069] (3) Instrument testing indicators Skin elasticity and firmness: Instrument: CK MPA580 multi-probe skin testing system (Germany).

[0070] Probes: Cutometer dualMPA580 (negative pressure suction method) for measuring elastic parameters (R2, R5 values); Reviscometer RVM600 (acoustic resonance method) for measuring compactness / density parameters.

[0071] Test areas: left / right cheeks.

[0072] Wrinkles, smoothness, and luster: Instrument: CanfieldVisia-CR skin analyzer (USA).

[0073] Indicators: Wrinkles count, Texture, Red / brown area (reflecting gloss and evenness).

[0074] Test areas: front and left and right sides of the entire face.

[0075] (4) Data processing and judgment criteria Data are expressed as mean ± standard deviation (Mean ± SD).

[0076] One-way ANOVA and t-tests were performed using SPSS software. Significance determination: Compared with D0, P<0.05 indicates significant improvement, and P<0.01 indicates highly significant improvement.

[0077] Intergroup comparison: Compared with the control group / blank group, P<0.05 indicates that the effect of the example group is significantly better than that of the control group.

[0078] Safety evaluation: Record any adverse reactions (erythema, itching, stinging, etc.) that occur during the trial. If a grade 3 or higher adverse reaction occurs, discontinue use immediately. Specific results are shown in Table 4 below (results after 28 days of continuous use): Table 4

[0079] Note: Compared with the blank matrix, # P < 0.05 ## P < 0.01.

[0080] The results show that the anti-aging and wrinkle-reducing essences obtained in Examples 1-3 of this invention can effectively improve the area of ​​skin wrinkles, reduce wrinkles, and at the same time, the skin elasticity, firmness and smoothness are also significantly improved, with better effects than comparative examples 1-4.

[0081] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A wrinkle composition characterized in that, It includes the following ingredients: oligopeptide-29, acetyl dipeptide-1 cetyl ester, palmitoyl hexapeptide-12, purple coneflower extract, oat extract and red clover extract.

2. The anti-wrinkle composition according to claim 1, characterized in that, The mass ratio of oligopeptide-29, acetyl dipeptide-1 cetyl ester, and palmitoyl hexapeptide-12 is 0.8-1.2:0.8-1.2:3-5.

3. The wrinkle composition according to claim 2, characterized in that, The mass ratio of oligopeptide-29, acetyl dipeptide-1 cetyl ester, and palmitoyl hexapeptide-12 is 1:1:

4.

4. The anti-wrinkle composition according to claim 1, characterized in that, The mass ratio of the purple coneflower extract, oat extract, and red clover extract is 3-5:5-7:0.5-1.

5.

5. The anti-wrinkle composition according to claim 4, characterized in that, The mass ratio of the purple coneflower extract, oat extract, and red clover extract is 4:6:

1.

6. The anti-wrinkle composition according to claim 1, characterized in that, The total mass ratio of the oligopeptide-29, acetyl dipeptide-1 cetyl ester, and palmitoyl hexapeptide-12 to the total mass ratio of the echinacea extract, oat extract, and red clover extract is 5-10:50-70.

7. The anti-wrinkle composition according to claim 6, characterized in that, The total mass ratio of the oligopeptide-29, acetyl dipeptide-1 cetyl ester, and palmitoyl hexapeptide-12 to the total mass ratio of the echinacea extract, oat extract, and red clover extract is 8:

60.

8. A method for preparing the anti-wrinkle composition according to any one of claims 1-7, characterized in that, The process includes the following steps: mixing the raw materials.

9. The use of the anti-wrinkle composition according to any one of claims 1-7 in the preparation of cosmetics.

10. The application according to claim 9, characterized in that, The dosage forms of the cosmetics include aqueous solutions, ointments, creams, emulsions, gels, aerosols, sprays, or injections.

Images